Join
Live feed
·
PRReleasevia Quantisnow
Can-Fite Biopharma Ltd logo

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months

ByQuantisnow·Wall Street's wire, on your screen.
CANF· Can-Fite Biopharma Ltd
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CANF (Can-Fite Biopharma Ltd) and more on Quantisnow.